Àrea privada
Contacte
Total de visites
| Visites | |
|---|---|
| Immuno-priming ... | 334 |
Total de visites per mes
| de juny 2025 | de juliol 2025 | d’agost 2025 | de setembre 2025 | d’octubre 2025 | de novembre 2025 | de desembre 2025 | |
|---|---|---|---|---|---|---|---|
| Immuno-priming ... | 15 | 19 | 10 | 3 | 8 | 150 | 3 |
Total de descàrregues del fitxer
| Visites | |
|---|---|
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_figura1.pdf | 169 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020.pdf | 31 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_figura5.pdf | 30 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_figura2.pdf | 30 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_taula1.pdf | 27 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_figura4.pdf | 24 |
| immuno_priming_durvalumab_bevacizumab_her2_negative_advanced_breast_cancer_pilot_clinical_trial_2020_figura3.pdf | 23 |
Visites per país
| Visites | |
|---|---|
| Índia | 145 |
| Estats Units | 70 |
| Brasil | 27 |
| Singapur | 18 |
| Hong Kong | 13 |
| Espanya | 12 |
| Xina | 9 |
| Alemanya | 8 |
| Vietnam | 7 |
| Austràlia | 5 |
Visites per ciutat
| Visites | |
|---|---|
| Mumbai | 145 |
| Ashburn | 17 |
| Singapore | 14 |
| Hong Kong | 13 |
| Chandler | 10 |
| Beijing | 8 |
| Chicago | 8 |
| St Louis | 5 |
| Sydney | 5 |
| Barcelona | 4 |
